Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 55,391 shares, an increase of 174.2% from the August 31st total of 20,198 shares. Currently, 1.5% of the company's stock are short sold. Based on an average daily volume of 43,645 shares, the short-interest ratio is presently 1.3 days.

An institutional investor recently bought a new stake in Pulmatrix stock. BlackRock Inc. purchased a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 54,899 shares of the biotechnology company's stock, valued at approximately $93,000. BlackRock Inc. owned about 1.50% of Pulmatrix as of its most recent SEC filing. Institutional investors and hedge funds own 11.84% of the company's stock.

NASDAQ PULM opened at $1.61 on Friday. The firm's fifty day moving average price is $1.57 and its 200 day moving average price is $1.54. The company has a market capitalization of $5.88 million, a price-to-earnings ratio of -1.46 and a beta of 1.90. Pulmatrix has a 12 month low of $1.16 and a 12 month high of $5.50.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($2.00) by $1.71.

Separately, Weiss Ratings lowered Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Pulmatrix, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other serious diseases. The company's approach is designed to deliver medicines directly to the lungs, potentially improving local drug exposure while limiting systemic side effects. Pulmatrix's technology platform, iSPERSE, is an engineered dry-powder formulation designed to enable the inhalation of a broad range of drug compounds. The platform has been used in the development of products including PUR1900, an inhaled formulation of itraconazole being investigated for respiratory fungal infections such as allergic bronchopulmonary aspergillosis, and other investigational therapies targeting pulmonary and related conditions. Based in Lexington, Massachusetts, Pulmatrix has historically focused on advancing inhaled treatments through preclinical and clinical development, while pursuing potential partnerships and commercialization opportunities.